Evolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury
September 05 2018 - 8:01AM
Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic
medicine, today announced the appointment of Ashwin K. Agarwal as
Vice President, Finance, Investor Relations, and Treasury,
effective immediately. Mr. Agarwal joins Evolus from Alder
BioPharmaceuticals where he served as Vice President, Corporate
Strategy and brings with him over 20 years of both operational and
corporate finance, investor relations, and accounting experience,
from his time at both early and late stage healthcare companies.
Earlier in his career, Mr. Agarwal served as
Vice President, Finance and Investor Relations at a medical
aesthetics start-up and also held roles of increasing
responsibility at Allergan for fifteen years, most recently as
Senior Director of Finance and Investor Relations. Mr. Agarwal
began his career at KPMG where he spent 3 years in the auditing
practice. He holds an MBA with an emphasis in Corporate Finance
from the University of Southern California Marshall School of
Business and a BA in Accounting from California State University,
Fullerton.
Lauren Silvernail, Chief Financial Officer and
EVP, Corporate Development of Evolus, commented, “Ashwin has deep
experience across a range of leadership roles in investor
relations, financing growth businesses, supporting business
development transactions and building successful long-term plans
with senior leadership. We are pleased to welcome him to our team
as we drive towards commercialization of DWP-450 in Spring
2019.”
About Evolus, Inc.
Evolus is a company dedicated to aesthetic
medicine focused on providing physicians and their patients with
expanded choices in aesthetic treatments and procedures. Evolus’
lead candidate DWP-450, also known by the chemical name
prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A
complex that was approved by Health Canada for the temporary
improvement in the appearance of moderate to severe glabellar lines
in adult patients under 65 years of age and is being evaluated for
marketing approval in the United States and other areas.
Forward-Looking Statements
Statements made in this press release that
relate to future plans, events, prospects or performance are
forward-looking statements as defined under the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words “planned,” “expect,” “believes,” “strategy,” “opportunity,”
“anticipates,” “outlook,” “designed,” and similar words. While
these forward-looking statements are based on the current
expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties,
assumptions and other factors that could cause actual results to
differ materially from the expectations expressed in this press
release, including the risks and uncertainties disclosed in Evolus’
periodic filings with the Securities and Exchange Commission,
including factors described in the section entitled “Risk Factors”
in its Annual Report on Form 10-K for the year ended December 31,
2017; its Quarterly Report on Form 10-Q for the Quarter ended June
30, 2018, as filed with the Securities and Exchange Commission on
March 29, 2018, May 10, 2018 and August 2, 2018, respectively, all
of which are available online at www.sec.gov. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Except as required by law,
Evolus undertakes no obligation to update or revise any
forward-looking statements to reflect new information, changed
circumstances or unanticipated events.
Evolus Contacts:
Investor Contact:
Ashwin Agarwal, EvolusTel: +1-949-284-4559Email:
IR@Evolus.com
Brian Johnston, The Ruth GroupTel: +1
646-536-7028Email: IR@Evolus.com
Media:Kirsten Thomas, The Ruth GroupTel: +1-508-280-6592Email:
kthomas@theruthgroup.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024